January 28, 2020

The Honorable Alex M. Azar II
Secretary
United States Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201

Dear Secretary Azar,

As organizations representing health care providers, patients, public health, scientists, and industry, we are writing to alert you to the latest significant evidence that the antibiotic market is in jeopardy —the December 27, 2019 Chapter 11 bankruptcy filing and restructuring of Melinta Therapeutics —a biotech company with four products on the market. While Melinta’s products remain available during this process, this is yet another sign that will drive investors away from this space. We implore you to take swift action to stabilize and strengthen the antibiotics market and make the investments necessary for a comprehensive response to antimicrobial resistance, including stewardship, diagnostics, surveillance, prevention and research.

The antibiotics market is in a state of crisis. Melinta is not an outlier—it is the second small antibiotics company, following Achaogen, to file for bankruptcy in 2019. The stock prices of the remaining small antibiotics companies with approved antibiotics make clear that additional bankruptcies are likely in 2020 unless federal action is taken. Small companies are particularly important in the antibiotic space as they are developing the majority of new medicines to address antimicrobial resistance (AMR). Many of these companies are struggling to secure private investment to bring these medicines to the market and patients. Additional failures of companies following successful approval will sap what little investment remains in this space with catastrophic consequences on an already inadequate pipeline.

Allowing the antibiotics market to collapse endangers modern medicine, public health and national security. Antibiotics underpin modern medicine—making interventions like cancer chemotherapy, organ and bone marrow transplants, and surgeries safe to perform. Without antibiotics, simple cuts can once again lead to amputations and even deaths. The death tolls of mass casualty events—whether natural or human-made—will increase substantially as we become unable to treat secondary infections that complicate wounds and burns.

We appreciate the initial steps taken by the administration to address antimicrobial resistance, including the new Medicare Condition of Participation requiring hospitals to implement stewardship programs, efforts to improve antibiotic reimbursement, strides in surveillance and infection prevention, and support for antibiotic development from the Biomedical Advanced Research and Development Authority and the National Institutes of Allergy and Infectious Diseases.

However, the magnitude of the problem requires far greater investment to ensure the sustainability of the antibiotics market. While current incentives have been successful at bringing important new antibiotics to market, they alone are insufficient and a package of incentives are needed to ensure new antibiotics can remain available to patients and to further strengthen the pipeline to bring about the innovation needed to meet current and future patient needs. New resources are also urgently needed
to support stewardship, surveillance and other public health activities to address antimicrobial resistance.

We appreciate your attention to the serious issue of antimicrobial resistance and the urgent need to save the antibiotics market in order to protect our national security, public health and modern medicine.

Sincerely,

Accelerate Diagnostics
Aequor
American Gastroenterological Association
American Thoracic Society
Association for Professionals in Infection Control and Epidemiology
Association of Public and Land-grant Universities
bioMerieux
Biotechnology Innovation Organization (BIO)
Cystic Fibrosis Foundation
Emory Antibiotic Resistance Center
HIV Medicine Association
Infectious Diseases Society of America
Making-A-Difference in Infectious Diseases
Merck
National Coalition of STD Directors
ONCORD, Inc.
Peggy Lillis Foundation
Peptilogics
Qpex Biopharma
Shionogi, Inc.
Society of Critical Care Medicine
Society of Infectious Diseases Pharmacists
Spero Therapeutics
Summit Therapeutics

The Foundation to Combat Antimicrobial Resistance

The Gerontological Society of America

The Pew Charitable Trusts

Trust for America's Health

Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR)

Venatorx Pharmaceuticals

Cc: Anthony Fauci, MD, FIDSA
    National Institutes of Health
    Director, National Institute for Allergy and Infectious Diseases
    Building 31, National Institutes of Health
    31 Center Drive, Room 7A03
    Bethesda, MD 20892-2520

Dr. Robert Redfield
    Director
    Centers for Disease Control and Prevention
    1600 Clifton Road
    Atlanta, Georgia 30329

Seema Verma, MPH
    Administrator
    Centers for Medicare & Medicaid Services
    Department of Health and Human Services
    200 Independence Avenue SW
    Washington, DC 20201

Dr. Stephen Hahn
    Commissioner
    U.S. Food and Drug Administration
    10903 New Hampshire Avenue
    Silver Spring, MD 20993

ADM Brett Giroir, MD
    Assistant Secretary for Health
    U.S. Health and Human Services Department
    200 Independence Avenue, SW
    Room 715-G
    Washington, DC 20201

Dr. Robert Kadlec
    Assistant Secretary of Preparedness and Response
    U.S. Department of Health and Human Services
    200 Independence Ave. SW
    Washington, DC 20201

Seema Verma, MPH
    Administrator
    Centers for Medicare & Medicaid Services
    Department of Health and Human Services
    200 Independence Avenue SW
    Washington, DC 20201

Dr. Robert Kadlec
    Assistant Secretary of Preparedness and Response
    U.S. Department of Health and Human Services
    200 Independence Ave. SW
    Washington, DC 20201

Dr. Robert Kadlec
    Assistant Secretary of Preparedness and Response
    U.S. Department of Health and Human Services
    200 Independence Ave. SW
    Washington, DC 20201